C
Cadrenal Therapeutics, Inc. (CVKD)
NCM – Real Time Price. Currency in USD
5.19
-0.33 (-6.02%)
At close: May 12, 2026, 4:00 PM EDT
5.29
+0.10 (1.93%)
After-hours: May 12, 2026, 5:59 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
5.19
-0.33 (-6.02%)
At close: May 12, 2026, 4:00 PM EDT
5.29
+0.10 (1.93%)
After-hours: May 12, 2026, 5:59 PM EDT
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
| Name | Position |
|---|---|
| Dr. James J. Ferguson FACC, M.D. | Chief Medical Officer |
| Dr. Matthew Boxer M.B.A., Ph.D. | Executive Vice President of Corporate Development |
| Mr. Jeffrey Cole | Chief Operating Officer |
| Mr. Quang X. Pham | Chairman & CEO |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 8-K | ea0289377-8k_cadrenal.htm |
| 2026-05-07 | 10-Q | ea0288837-10q_cadrenal.htm |
| 2026-04-30 | 8-K | ea0288376-8k_cadrenal.htm |
| 2026-04-21 | S-3 | ea0286431-s3_cadrenal.htm |
| 2026-04-06 | D | |
| 2026-03-31 | 8-K | ea0284258-8k_cadrenal.htm |
| 2026-03-31 | 10-K | ea0283741-10k_cadrenal.htm |
| 2026-03-12 | 8-K | ea0281315-8k_cadrenal.htm |
| 2026-02-24 | 8-K | ea0278072-8k_cadrenal.htm |
| 2025-12-31 | D |